Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has entered into partnership with the AstraZeneca Pharma India for the distribution of dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is AstraZeneca India’s leading diabetes medicine.

Under the agreement, the company will promote and distribute dapagliflozin under the brand name ‘Oxra’. AstraZeneca India markets dapagliflozin under the brand name ‘Forxiga’ and under the terms of the agreement, both companies will promote, market & distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.

The company will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name ‘Oxramet’, following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin.

Sun Pharma is world's fifth largest specialty generic and India's top pharmaceutical company. With a vertically integrated business, economies of scale, an extremely skilled team enabling delivery of quality products at affordable prices and trusted by customers and patients in over 150 countries globally. The company's global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres worldwide and a multi-cultural workforce representing more than 50 nationalities.